CSPC Pharmaceutical Group Limited ADR logo

CSPC Pharmaceutical Group Limited ADR (CVGU)

Market Open
19 Jun, 20:00
XFRA XFRA
2. 84
+0.14
+5.1852%
58.91B Market Cap
11.41 P/E Ratio
0.23% Div Yield
10 Volume
0 Eps
2.7
Previous Close
Add Transaction
Day Range
2.84 2.84
Year Range
2.7 5.1
Want to track CVGU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CVGU trading today higher at €2.84, an increase of 5.1852% from yesterday's close, completing a monthly decrease of -4.0541% or -€0.12. Over the past 12 months, CVGU stock lost -15.9763%.
CVGU pays dividends to its shareholders, with the most recent payment made on Aug 01, 2025. The next announced payment will be in In 1 month on Jul 29, 2026 for a total of €0.07673.
The last earnings report, released on May 27, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
CSPC Pharmaceutical Group Limited ADR has completed 3 stock splits, with the recent split occurring on Dec 10, 2020.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

CVGU Chart

People also search for

Amgen Inc. Canadian Depositary Receipt
15.5
0%
Gilead Sciences Inc. Canadian Depositary Receipt
15.5
+1.3072%
Abbott Laboratories CDR
9.5
-0.5236%
Novo Nordisk A/S
11.1
-9.0164%
Pfizer Inc.
5.85
0%

CSPC Pharmaceutical Group Limited ADR (CVGU) FAQ

What is the stock price today?

The current price is €2.84.

On which exchange is it traded?

CSPC Pharmaceutical Group Limited ADR is listed on XFRA.

What is its stock symbol?

The ticker symbol is CVGU.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.23%.

What is its market cap?

As of today, the market cap is 58.91B.

Has CSPC Pharmaceutical Group Limited ADR ever had a stock split?

CSPC Pharmaceutical Group Limited ADR had 3 splits and the recent split was on Dec 10, 2020.

CSPC Pharmaceutical Group Limited ADR Profile

Pharmaceuticals Industry
Healthcare Sector
Lei Cai CEO
XFRA Exchange
US12591J2078 ISIN
CN Country
21,400 Employees
25 Jun 2026 Last Dividend
10 Dec 2020 Last Split
- IPO Date

Overview

CSPC Pharmaceutical Group Limited, established in 1992 and headquartered in Shijiazhuang, the People's Republic of China, is a prominent investment holding company specializing in the pharmaceutical sector. The company stands out for its comprehensive involvement in researching, developing, manufacturing, and distributing pharmaceutical products across a wide geographical stretch that includes the People's Republic of China, other Asian regions, North America, Europe, and beyond in the global market. Operating through its strategic divisions—Finished Drugs, Bulk Products, and Functional Food and Others—CSPC Pharmaceutical has cemented its reputation as a leading provider of a variety of pharmaceutical solutions. A significant milestone in the company's history is its strategic partnership with Pfizer Inc., aimed at launching a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, showcasing its commitment to contributing to global health crises solutions. Originally known as China Pharmaceutical Group Limited, the company rebranded to CSPC Pharmaceutical Group Limited in March 2013 to better reflect its expansive scope and ambitions.

Products and Services

  • NBP soft capsules and injections: Designed for the treatment of acute ischemic stroke, offering crucial intervention in the early stages of stroke management.
  • Oulaining capsules and injections: Prescribed for mild to moderate memory and mental impairment, enhancing cognitive functions in affected individuals.
  • Enxi: A medication aimed at treating adult idiopathic Parkinson's disease, offering relief and improving the quality of life for patients.
  • Duomeisu: Focused on the treatment of lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors, showcasing the company's dedication to cancer care.
  • Jinyouli: Developed to prevent leucopenia and infection induced by chemotherapy, supporting patients through their cancer treatment process.
  • Keaili: Another of the company’s oncology offerings, specifically targeting breast cancer treatment.
  • Antibiotics, Vitamin C, and Caffeine APIs: Critical components in the development of a range of pharmaceutical applications, highlighting CSPC's diverse approach to health solutions.
  • Functional food and glucose products: Expanding beyond pharmaceuticals, these offerings cater to the broader health and wellness sector, providing nutritional and health maintenance options.
  • Healthcare services: Beyond products, CSPC offers a spectrum of healthcare services, reinforcing its comprehensive approach towards healthcare provision and patient support.

Contact Information

Address: No. 226 Huanghe Street
Phone: 86 31 1870 37015